NCT07217301View on ClinicalTrials.gov

IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

November 1, 2028

Study Completion Date

December 1, 2029

Conditions
iO Resistant sqNSCLC
Interventions
DRUG

IBI363

Investigational product will be administered by IV infusion

DRUG

Control Arm

Comparator product will be administered by IV infusion

Trial Locations (2)

94043

Fortvita Biologics, Mountain View

200030

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

lead

Fortvita Biologics (USA)Inc.

INDUSTRY

NCT07217301 - IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed | Biotech Hunter | Biotech Hunter